目的 研究消癌平口服液联合贝伐珠单抗注射液治疗中晚期非小细胞肺癌的临床疗效。方法 选取2016年1月—2019年1月河南大学第一附属医院收治的128例中晚期非小细胞肺癌患者，将所有患者随机分为对照组和治疗组，每组各64例。患者入院后均给予TC方案（卡铂+紫杉醇）基础治疗，对照组患者第1天静脉滴注贝伐珠单抗注射液，7.5 mg/kg；治疗组患者在对照组基础上口服消癌平口服液，10 mL/次，3次/d。21 d为1个疗程，两组患者持续治疗4个疗程。观察两组的临床疗效，比较两组的血清癌胚抗原（CEA）、神经特异性烯醇化酶（NSE）、糖类抗原125（CA125）水平、Karnofsky（KPS）评分、无进展生存时间（PFS）、总生存时间（OS）和不良反应发生情况。结果 治疗后，治疗组疾病控制率（DCR）（78.12% vs 67.19%）和客观缓解率（ORR）（64.06%vs 51.56%）显著高于对照组（P<0.05）。治疗后，两组患者血清CA125、CEA、NSE水平显著降低（P<0.05）；并且治疗组血清CA125、CEA、NSE水平降低较多（P<0.05）。治疗后，两组患者KPS评分显著升高（P<0.05）；并且治疗组KPS评分升高较多（P<0.05）。治疗后，治疗组患者OS和PFS显著高于对照组（P<0.05）。治疗过程中，治疗组胃肠道反应、血小板降低、白细胞降低和肝功能异常发生显著低于对照组（P<0.05）。结论 消癌平口服液联合贝伐珠单抗注射液治疗中晚期非小细胞肺癌具有较好的治疗效果，能够提高患者生活质量，降低血清肿瘤标志物水平，值得在临床上推广应用。

Objective To study the clinical efficacy of Xiaoaiping Oral Liquid combined with Bevacizumab Injection in treatment of advanced non-small cell lung cancer. Methods Patients (128 cases) with advanced non-small cell lung cancer in the First Affiliated Hospital of Henan University from January 2016 to January 2019 were randomly divided into control and treatment groups, and each group had 64 cases. Patients were treated with TC regimen (carboplatin + paclitaxel). Patients in the control group were iv administered with Bevacizumab Injection at the first day, 7.5 mg/kg. Patients in the treatment group were po administered with Xiaoaiping Oral Liquid on the basis of the control group, 10 mL/time, three times daily. A course had 21 days, and patients in two groups were treated for 4 courses. After treatment, the clinical efficacies were evaluated, and serum levels of CEA, NSE, and CA125, KPS score, progression-free survival time (PFS), total survival time (OS), and adverse reactions were compared between two groups. Results After treatment, DCR (78.12% vs 67.19%) and ORR (64.06% vs 51.56%) in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the serum levels of CEA, NSE and CA125 in the two groups were significantly reduced (P<0.05). And the tumor markers in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, KPS scores in two groups were significantly decreased (P<0.05), and the KPS score in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, PFS and OS in the treatment group were significantly higher than those in the control group (P<0.05). The incidence of gastrointestinal reaction, thrombocytopenia, leukopenia and liver dysfunction in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Xiaoaiping Oral Liquid combined with Bevacizumab Injection has clinical curative effect in treatment of advanced non-small cell lung cancer, can improve the quality of life of patients and reduce the serum levels of tumor markers, which is worthy of clinical application.

R977

开封市科技发展计划项目（1806005）